Table 4. Characteristics of VLBW infants with ROP requiring treatment according to the treatment methods.
| Characteristics | Only ROP operation (n = 147) | Only anti-VEGF treatment (n = 39) | Operation+ anti-VEGF (n = 45) |
|---|---|---|---|
| Treatment proportion (%) | 63.6 | 16.9 | 19.5 |
| Gestational age | |||
| Mean (week) | 25.5 ± 3.3 | 25.5 ± 3.4 | 25.0 ± 3.3 |
| 22-23 | 19 (12.9%) | 4 (10.3%) | 11 (24.4%) |
| 24-25 | 69 (46.9%) | 18 (46.2%) | 20 (44.4%) |
| 26-27 | 35 (23.8%) | 9 (23.1%) | 8 (18.2%) |
| ≥ 28 | 24 (16.3%) | 8 (20.5%) | 6 (13.6%) |
| Birth weight | |||
| Mean (g) | 828 ± 254 | 814 ± 238 | 761 ± 239 |
| ≤ 499 | 7 (4.8%) | 3 (7.7%) | 4 (8.9%) |
| 500-749 | 55 (37.4%) | 13 (33.3%) | 19 (42.2%) |
| 750-999 | 53 (36.1%) | 17 (43.6%) | 15 (33.3%) |
| ≥ 1,000 | 32 (21.8%) | 6 (15.4%) | 7 (15.6%) |
| Male | 61 (52.6%) | 13 (46.4%) | 26 (68.4%) |
| ROP severity | |||
| Stage ≤ 2 (%) | 31 (21.0) | 11 (28.2) | 7 (15.6) |
| Stage ≥ 3 (%) | 116 (79.0) | 28 (71.8) | 38 (84.4) |
Data are presented as n (%) or mean±standard deviation. ROP, retinopathy of prematurity; VEGF, vascular endothelial growth factor.